Harbin Jixianglong Biotech Co., Ltd. FDA Recalls

2 recalls on file across drugs, 0 of them Class I and 2 still open. This firm is not matched to a listed company.

Newest first

Class I is the FDA's most serious grade: a reasonable probability of serious harm or death.

Product	Reason	Class	Initiated
Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 843Class IIFeb 13, 2026CGMP Deviations This recall has been initiated due to failin	CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial end	Class IIDrugs	Feb 13, 2026
Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 8438Class IIFeb 13, 2026CGMP Deviations This recall has been initiated due to failin	CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial end	Class IIDrugs	Feb 13, 2026